Sugi Predict
/ Targets
/ PDS5B
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to PDS5B by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Phenoxybenzamine Versus Doxazosin in PCC Patients |
PHASE4 | COMPLETED |
| Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment |
PHASE2/PHASE3 | RECRUITING |
| A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects |
PHASE1/PHASE2 | COMPLETED |
| Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer |
PHASE2 | UNKNOWN |
| Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) |
PHASE2 | RECRUITING |
| Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100 |
PHASE1/PHASE2 | COMPLETED |
| Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation |
PHASE2 | UNKNOWN |
| PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation |
PHASE2 | UNKNOWN |
| Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL) |
PHASE2 | COMPLETED |
| Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability |
PHASE2 | ACTIVE_NOT_RECRUITING |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel |
PHASE1 | COMPLETED |
| Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer |
PHASE1 | COMPLETED |
| Study of ABT-751 in Patients With Refractory Hematologic Malignancies |
PHASE1 | COMPLETED |
| Better Delineation of CDK13 Related Phenotype and Epigenetic Signature. |
nan | UNKNOWN |
| Endocrine Disruptors and Life STILe in Breast Cancer Development |
nan | UNKNOWN |
| Genetics of Prostate Cancer in Young Patients |
nan | COMPLETED |
| Enhanced Linkage Maps From Family-Based Genetics Studies |
nan | COMPLETED |
| CDH1 Germline Mutations in Lobular Breast Cancer |
nan | COMPLETED |
| PCD New Gene Discovery |
nan | COMPLETED |
| Promoting Men's Adherence to BRCA1/2 Germline Genetic Testing |
nan | COMPLETED |
| Study of the Effect of Innate on the Inflammatory Response to Endotoxin |
nan | RECRUITING |
| Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer |
nan | COMPLETED |
| Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients |
nan | RECRUITING |
| Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease |
nan | UNKNOWN |
| Identification of Genetic Basis of Atrioventricular Conduction Defects: From Congenital Forms to Degenerative Forms |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a PDS5B binder may also engage these)